cGxP.wire https://validator.w3.org/feed/docs/rss2.html Satellite Bio Receives FDA Rare Pediatric Disease Designation for SB-101 Aqua Medical Appoints Bob Haggerty to Lead Diabetes Growth Rhythm Pharmaceuticals Advances RM-718 with Promising Phase 2 Obesity Trial Results Harmony Biosciences Reports Record Q2 2026 Revenue, Shares Positive BP-205 Phase 1 Data Galaxy Therapeutics Secures CE Mark for SEAL System Cirrus Expands Ocular Immunology Through SERI Partnership AsymBio Secures $184 Million to Expand Global CDMO Growth Dianthus Unveils DNTH312 Dual-Target Autoimmune Therapy Nurix and Sanofi Advance Oral STAT6 Degrader into Phase 1 Clinical Development BioLab Publishes Membrane Wrap Study for Pressure Ulcers Innogen Gains PIC/S GMP Certification for Efsubaglutide Otsuka Advances VOYXACT with Landmark Two-Year Phase 3 IgAN Results Pathos AI Partners with AstraZeneca to Advance AZD4241 for ER+ Breast Cancer 4Moving Biotech Targets Synovitis with Intra-Articular GLP-1 Therapy Zydus Secures USFDA Approval for Indocyanine Green Dr. Reddy’s Expands Access to Immunotherapy for Rare Head and Neck Cancer SOPHiA GENETICS Partners with AstraZeneca on CDx Dr. Reddy’s Laboratories Secures U.S. FDA Approval for Rituximab Biosimilar CND Life Sciences Secures Growth Funding for Syn-One Test Evexta Bio and Roche Partner to Evaluate Rupitasertib Combination in Advanced Breast Cancer Marengo Advances TriSTAR Pipeline with Ipsen Collaboration Sanofi’s MenQuadfi Receives EU Approval for Infants From Six Weeks of Age Nurix Therapeutics Enrolls First Patient in Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg Nuvation Bio Showcases IBTROZI Data at Global Oncology Meets Allergan Aesthetics Secures FDA Review for BOTOX Cosmetic CervoMed Secures UK ILAP Innovation Passport for Neflamapimod CU Anschutz Trial Shows AI Improves Hospital Oxygen Therapy Pathos AI Expands Oncology Pipeline with JSKN016 Licensing Curium to Merge with Lantheus in $8B Radiopharma Deal Haemonetics Study Validates VASCADE MVP XL Performance AIM ImmunoTech Advances DURIPANC Trial with Final Dosing Milestone InnoCare Secures China Breakthrough Therapy Status for Marginal Zone Lymphoma Therapy Candel Therapeutics Announces Extended Phase 3 Data Presentation at ASTRO 2026 Design Therapeutics Reports RESTORE-FA Progress and Advances GeneTAC® Pipeline Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide for MASH Zevra Therapeutics Publishes Four-Year MIPLYFFA Real-World NPC Data Rocket Pharmaceuticals Reports Positive RP-A501 Safety Update Zai Lab Receives FDA Orphan Drug Designation for Zoci Meitheal Gains FDA Approval for Garzulys Insulin Biosimilar Seaport Therapeutics Reports Q2 Progress Across Neuropsychiatry Pipeline Biocon Launches Yesafili Biosimilar to Eylea in U.S. Akebia Launches Phase 2 Ebribafusp Trial in Kidney Diseases Can-Fite Launches Phase 2 Piclidenoson Trial for Lowe Syndrome Opus Genetics Completes Enrollment in OPGx-LCA5 Phase 3 Trial Intelligent Bio Solutions Advances FDA 510(k) Drug Screening Study Tonix Pharmaceuticals Receives FDA Alignment for TNX-4800 Phase 2 Trial Adlai Nortye Receives HREC Approval for AN4035 Phase I Trial Genprex and Roche Diagnostics Advance TROP2 Biomarker Strategy Ceribell Secures CMS NTAP for Delirium Monitor System Keenova Publishes New XIAFLEX Data in Peyronie’s Disease